FDA Approves OPDIVO QVANTIG — E.R. Squibb & Sons, L.L.C.

On December 27, 2024, the FDA approved **E.R. Squibb & Sons, L.L.C.**’s OPDIVO QVANTIG (nivolumab and hyaluronidase-nvhy), a novel subcutaneous formulation of its flagship immunotherapy, which is poised to broaden market accessibility by enhancing the convenience and speed of administration versus the standard intravenous regimen. This regulatory milestone offers a strategic competitive advantage in the rapidly evolving oncology landscape, driven by the potential to streamline hospital workflows and improve patient adherence to life-saving treatment protocols.